Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.
Brander C, Yang OO, Jones NG, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay C, Buchbinder S, Bergmann CC, Zweerink HJ, Wolinsky S, Blattner WA, Kalams SA, Walker BD. Brander C, et al. Among authors: buchbinder s. J Virol. 1999 Dec;73(12):10191-8. doi: 10.1128/JVI.73.12.10191-10198.1999. J Virol. 1999. PMID: 10559335 Free PMC article.
Safety and toxicity of nonoxynol-9 gel as a rectal microbicide.
Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, Fleming TR, Buchbinder S, Haggitt RC, Levine H, Kelly CW, Celum CL. Tabet SR, et al. Among authors: buchbinder s. Sex Transm Dis. 1999 Nov;26(10):564-71. doi: 10.1097/00007435-199911000-00005. Sex Transm Dis. 1999. PMID: 10560720 Clinical Trial.
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. Celum CL, et al. Among authors: buchbinder sp. J Infect Dis. 2001 Jan 1;183(1):23-35. doi: 10.1086/317658. Epub 2000 Dec 8. J Infect Dis. 2001. PMID: 11106536
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.
Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo MM, Shea A, Newman M, Fikes J, Sidney J, Wentworth P, Chesnut R, Eldridge RL, Rosenberg ES, Robbins GK, Brander C, Sax PE, Boswell S, Flynn T, Buchbinder S, Goulder PJ, Walker BD, Sette A, Kalams SA. Altfeld MA, et al. Among authors: buchbinder s. J Virol. 2001 Feb;75(3):1301-11. doi: 10.1128/JVI.75.3.1301-1311.2001. J Virol. 2001. PMID: 11152503 Free PMC article.
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Belshe RB, et al. Among authors: buchbinder s. J Infect Dis. 2001 May 1;183(9):1343-52. doi: 10.1086/319863. Epub 2001 Apr 10. J Infect Dis. 2001. PMID: 11294665 Clinical Trial.
426 results